Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

21 Feb 2013
Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

14 Feb 2013
Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

14 Feb 2013
Dyax fourth quarter total revenues increase to $16.0 million

Dyax fourth quarter total revenues increase to $16.0 million

14 Feb 2013
Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

13 Feb 2013
Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

12 Feb 2013
Glimmer of hope for imatinib-resistant GIST

Glimmer of hope for imatinib-resistant GIST

7 Feb 2013
Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

6 Feb 2013
Scientists produce monoclonal antibody in tobacco plants that neutralizes rabies viruses

Scientists produce monoclonal antibody in tobacco plants that neutralizes rabies viruses

2 Feb 2013
Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

1 Feb 2013
Teva terminates collaboration with CureTech

Teva terminates collaboration with CureTech

31 Jan 2013
Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

31 Jan 2013
Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

28 Jan 2013
FDA accepts Genzyme’s LEMTRADA sBLA for review

FDA accepts Genzyme’s LEMTRADA sBLA for review

28 Jan 2013
Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

28 Jan 2013
New model of tau pathology spread

New model of tau pathology spread

19 Jan 2013
FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

16 Jan 2013
Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

11 Jan 2013
arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

7 Jan 2013
Adrenomed creates Adrecizumab to decrease death rates from sepsis

Adrenomed creates Adrecizumab to decrease death rates from sepsis

3 Jan 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback